AdipoPharma Targets Root Cause Of Diabetes With First ‘Adipeutic’ Drug Candidate

05 Aug 2022

• By Ayisha Sharma

Emerging Company Profile: The French biotech is developing a constrained peptide that targets an interaction in body fat tissue in the hopes of treating type 2 diabetes.

ECP AdipoPharma — Adipose Cells Affect Whole-Body Lipid Homeostasis • Source: Shutterstock

AdipoPharma SAS is developing what it hopes will be the first drug candidate to target adipose tissue in an attempt to address the root cause of type 2 diabetes, namely insulin resistance.

The company’s approach is based on more than a decade of research into the ultra-rare genetic disorder Alström syndrome, which...